ARS-Patent protected Novo Nordisk A/S’s interests in a patent dispute

ARS-Patent represented the interests of Novo Nordisk A/S in the patent dispute over the Rospatent’s decision on extension of the validity term of a patent related to Insulin degludec owned by Novo Nordisk A/S. Recently, a request of the plaintiff (Geropharm LLC) for the cassation appeal to be considered by the Court Board of the Supreme Court of the Russian Federation was rejected. That was the final step of the case.

During the legal proceedings, Kirill Osipov, the Head of Legal Department, being the authorized representative of the patentee showed the Court for Intellectual Property Rights, which considered Geropharm’s lawsuit as the first-instance court, that the term for filing such lawsuit as set by Russian law was missed by the plaintiff. In view of arguments and pieces of evidence provided, the Court rejected the lawsuit. The Court’s decision was also upheld by further court instances.

The case was widely discussed in the mass-media.

Make an enquiry

Latest News

Transactions in connection with a patent, trademark, copyright, or other form of intellectual property protection in Russia and U.S.


The U.S. Department of the Treasury’s Office of Foreign Assets Control (“OFAC”) issued a General License No. 31 dated May 5, 2022 which makes an...

Read more
Parallel import goods published by the Russian Government


The list of goods (groups of goods), in respect of which the requirements for the protection of intellectual rights by the right holders (patent holde...

Read more

View all our News


INTA 2022 Annual Meeting Live+


Pavel Vorobev, the Client Manager and Patent Attorney of ARS-Patent, will be attending in person INTA’s 144th Annual Meeting which will take place i...

Read more
Meet with us at IIPLA 2021 USA in Las Vegas


Pavel Vorobev, the Client Manager and Patent Attorney of ARS-Patent, will be attending IIPLA 2021 USA on November 3-5, 2021 in Las Vegas. Internati...

Read more

See all Events

Back top